



Pathological Mechanisms of Diabetic Nephropathy

Guest Editor:

Dr. Isha Sharma

Department of Pathology,
Northwestern University,
Chicago, IL 60611, USA

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

We welcome submissions to this Special Issue on the pathological mechanism of diabetic nephropathy. Detailed knowledge of signaling mechanisms would allow increasingly targeted therapy for DN patients. Therefore, we welcome authors to address the following themes:

- Signaling mechanisms leading to hyperglycemia or obesity-driven tubulointerstitial fibrosis.
- Hypertension-induced renal injury in diabetes. The cross-talk between metabolic and hemodynamic pathways in amplifying diabetes-related renal injury.
- Lipid- or glucose-driven metabolic-sensor or post-translational perturbations that leads to renal fibrosis.
- Glucagon-like peptide-1 receptor agonist in dampening the development and progression of diabetes-mediated renal disorders.
- Role of various types of cell death in diabetes and obesity-driven nephropathy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI